Jennifer A. Doudna - 27 Jul 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: 10%+ Owner
Issuer ticker: SCTX
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 16:21:49 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ David L. Parrot, Attorney-in-Fact

Key filing fact

Jennifer A. Doudna filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 29 Jul 2026.

Key facts

This page summarizes Jennifer A. Doudna's Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2026, 16:21.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001739090 Primary reporting owner

Doudna Jennifer A

Relationship: 10%+ Owner
Address: C/O SCRIBE THERAPEUTICS INC., 1150 MARINA VILLAGE PARKWAY, ALAMEDA
Signature: /s/ David L. Parrot, Attorney-in-Fact
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +12,511
Change %: +2.1%
Price
Shares after: 603,547
Date: 27 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTX transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -74,088
Change %: -100%
Price
Shares after: 0
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,511
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.